Nociscan is Aclarion’s augmented intelligence platform that measures disc health biomarkers and aims to help physicians identify the location of chronic back pain. The partnership will give surgeons one platform to access data.
“Evolving spinal technologies through innovation requires discipline, time, know-how and resources,” Pat Miles, CEO of Alphatec, said in the release. “This partnership with Aclarion reflects our belief in the importance of biochemical markers within the treatment paradigm. Nociscan is exactly the type of innovation that can advance our shared goal of integrating and advancing technologies that improve the predictability and reproducibility of spine care.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.